Insights

Scale-down models have become an increasingly common development tool, especially in the bioprocessing industry. Read our eBook to discover our approach to the challenge of scaling up scale down models.

Synthetic biology remains nascent, yet full of promise. The idea of using rational engineering approaches to design biology has the potential to solve some of humanity’s biggest challenges, such as securing food supplies...

From almost three years of pandemic restrictions to a three-day biology bonanza. Senior Biomedical Engineer Ellen Simmons gets back on the live conference trail with a visit to Built With Biology, formerly SynBioBeta. Here she shares her experiences – and enthusiasm for helping to drive the biotech ecosystem forwards… 

Our brand relaunch has landed just as we ramp up our commitment to The Engine, the ambitious venture capital firm spun out of MIT (Massachusetts Institute of Technology) to support ‘Tough Tech’ companies and solve key challenges in climate change, human health and advanced systems. What’s particularly energizing is that as a strategic partner, we get to engage with founders of disruptive start-ups who are so passionate, driven and mission focused. The alignment with our own renewed purpose couldn’t be stronger.

Fresh from an in-person visit to BioData World Conference 2021, Andrew Goulter discusses the role big pharma is playing in unlocking a complex new healthcare ecosystem. His hope? That effective data sharing and democratised access will deliver advantages for healthcare professionals and patients alike… 
 

Cambridge Consultants' Mike Dunkley, SVP, Bioinnovation, hosts a panel with industry leaders from Kytopen, CATALOG and Galy to explore transformative technologies for cell transfection, lab-grown cotton and DNA data storage. 

Cell and gene therapy is hailed as the future of 21st century medicine but is currently too expensive to be widely used. As a principal scientist in bioinnovation, I’ve been part of a team addressing this issue in an ambitious project with exciting potential…

PureSentry: Can real-time contamination detection transform cell therapy manufacture? 

This paper explains how ‘turning trash into cash’ provides opportunity for companies to gain first-mover advantage in several fields. With a clear, problem/solution approach, it outlines a method that be considered simply as a way to capture carbon – but is more likely to yield benefits in the creation of valuable bio-derived compounds.

Luis Diaz-Santana, Head of Ophthalmology at Cambridge Consultants, presented at OIS European Showcase virtual conference. Watch his presentation to hear his thoughts on if Europe really is an innovation powerhouse in ophthalmology.

The ambition to reduce or eliminate single-use plastics from the world’s supply chains is of course as laudable as it is essential. I’m proud to be part of a team of colleagues dedicated to doing something about it – by creating a guide that is helping innovators switch to alternatives.

We’re thrilled to be a part of the CGT Catapult, working with 20 brilliant companies to accelerate the technology development for cell and gene therapy manufacturing.